

Special Issue

New Insights in Biliary Tract Cancers Therapy

Message from the Guest Editor

Biliary tract cancers (BTCs) are an aggressive and assorted group of malignancies which arise from the epithelium of the biliary ducts and that represent about 3% of all gastrointestinal tumors. Depending on the site of origin, they are classified as intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (PCC), distal cholangiocarcinoma (DCC), and gallbladder cancer (GBC). Regardless of their location, BTCs are characterized by a dismal prognosis, with high rate of local invasion and metastatic spreading. However, the classification guides the management and treatment strategy. We are pleased to invite you to contribute to this Special Issue of *Cancers* titled “New Insights in Biliary Tract Cancers Therapy” that aims to highlight the emerging evidence and recent development in the treatment strategy for biliary tract cancers. This Special issue of *Cancers* therefore encompasses new research articles and timely reviews regarding the surgical approach, preoperative management, clinical and molecular prognostic factors, and systemic and local therapies.

Guest Editor

Dr. Simone Conci

Division of General and Hepatobiliary Surgery, Department of Surgery, Dentistry, Pediatrics and Gynaecology, University of Verona, 37134 Verona, Italy

Deadline for manuscript submissions

closed (31 March 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/99580

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)